United States Tuberculosis Drug Market 2025 | Growth Drivers, Market Forecast, Competitive Landscape & Business Opportunities

Market Size and Growth

Tuberculosis Drug Market was valued at US$ 1,755.29 million in 2021 and is estimated to reach US$ 2,407.35 million by 2031, growing at a CAGR of 9.68% during the forecast period (2024-2031).

Recent Mergers and acquisitions

United States:

✅ In July 2025, the Global Fund announced a 25% price reduction for pretomanid produced by Lupin, bringing the cost per treatment course down from USD $224 to USD $169. This initiative aims to enhance affordability and accessibility of TB treatments in low- and middle-income countries.

✅ In June 2025, the National Institute of Allergy and Infectious Diseases (NIAID) approved new concepts for Tuberculosis Research Units under its Division of Microbiology and Infectious Diseases (DMID). This move is expected to bolster research and development efforts in TB therapeutics.

✅ In May 2025, the Global Fund to Fight AIDS, Tuberculosis and Malaria reported a record number of 7.4 million people treated for TB in 2024, reflecting significant progress in global TB treatment coverage.

✅ In May 2025, Hamlet BioPharma announced progress in tuberculosis therapy, securing new patents to develop scientific discoveries into drugs for the treatment of cancer and infections, including TB

Japan:

✅ In August 2025, Japan's Ministry of Health, Labour and Welfare invested an additional USD 1 million in the Global Antibiotic Research and Development Partnership (GARDP), bringing its total investment to USD 10 million since 2020. This funding supports the development of new antibiotics, including those targeting TB.

✅ In July 2025, the UNITE4TB partnership completed the first wave of recruitment for its PARADIGM4TB trial, which is testing 14 drug regimens to accelerate the development of new treatments for TB.

✅ In June 2025, the Global Health Innovative Technology Fund (GHIT Fund) announced an investment of JPY 800 million (approximately USD 5.5 million) in malaria and TB research and development projects, aiming to advance the development of new treatments and diagnostics.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/tuberculosis-drug-market?sb

Tuberculosis Drugs are medications used to treat infections caused by Mycobacterium tuberculosis. Standard therapy includes first-line antibiotics such as isoniazid, rifampicin, ethambutol, and pyrazinamide, aimed at eliminating the bacteria, preventing drug resistance, and reducing transmission while ensuring patient recovery.

Key Players:

=> Pfizer Inc., Lupin Laboratories Ltd, AstraZeneca, Novartis, Cipla, Alkem Laboratories, Cadila pharmaceuticals, Johnson & Johnson, Sanofi, Macleod Pharmaceuticals and more.

Growth Forecast Projected:

The Global Tuberculosis Drug Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Tuberculosis Drug Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=tuberculosis-drug-market

Key Segments:

➥ By Therapy Type: First Line Drugs Therapy, Second Line Drugs Therapy, Combination Drugs Therapy
➥ By Type: Latent TB Type, Active Type

Regional Analysis for Tuberculosis Drug Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Tuberculosis Drug producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Tuberculosis Drug revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/tuberculosis-drug-market?sb

FAQ

What is the current size of the Tuberculosis Drug Market?

A: In 2021, the Tuberculosis Drug Market was valued at US$ 1,755.29 million , reflecting its strong industry presence.

Q2: How large is the Tuberculosis Drug Market expected to be by 2031?

A: By 2031, industry forecasts suggest the Tuberculosis Drug Market will grow to around US$ 2,407.35 million, demonstrating significant expansion.

Q3: What is the growth rate of the Tuberculosis Drug Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 9.68% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.